Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/08/21
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19GlobeNewsWire • 07/14/21
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI ConferenceGlobeNewsWire • 06/02/21
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical OfficerGlobeNewsWire • 05/19/21
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/21
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer PositionGlobeNewsWire • 03/09/21
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare ConferenceGlobeNewsWire • 03/08/21
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCLGlobeNewsWire • 03/01/21
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct OfferingPRNewsWire • 12/18/20
Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical TrialsPRNewsWire • 12/02/20
Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial ResultsPRNewsWire • 11/13/20
Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug ProductPRNewsWire • 08/31/20
Qualigen Therapeutics, Inc. (QLGN) CEO Michael Poirier on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/18/20
Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal Year 2021 Financial Results; Has $16 Million in Cash on Hand as of TodayPRNewsWire • 08/14/20
Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 08/04/20
Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 08/02/20
Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug CandidatesPRNewsWire • 07/22/20